



FUSION PROTEIN TECHNOLOGIES FOR BIOPHARMACEUTICALS

APPLICATIONS AND CHALLENGES

EDITED BY STEFAN R. SCHMIDT

WILEY

FUSION PROTEIN TECHNOLOGIES FOR BIOPHARMACEUTICALS

Applications and Challenges

Edited by

STEFAN R. SCHMIDT

WILEY

Copyright © 2013 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.

Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Fusion protein technologies for biopharmaceuticals : applications and challenges / edited by Stefan R. Schmidt.
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-64627-4 (cloth)

1. Schmidt, Stefan R.

[DNLM: 1. Recombinant Fusion Proteins—therapeutic use. 2. Drug Carriers.

3. Immunotoxins—pharmacokinetics. 4. Immunotoxins—therapeutic use. 5. Protein Engineering.

6. Recombinant Fusion Proteins—pharmacokinetics. QU 450]

615.7—dc23

2012039440

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTENTS

PREFACE	xxiii
CONTRIBUTORS	xxv
PART I INTRODUCTION	1
1 Fusion Proteins: Applications and Challenges	3
<i>Stefan R. Schmidt</i>	
1.1 History, 3	
1.2 Definitions and Categories, 4	
1.3 Patenting, 5	
1.4 Design and Engineering, 6	
1.4.1 Orientation of Fusion Proteins, 6	
1.4.2 Linker Engineering, 7	
1.4.3 Oligomerization of Fusion Proteins, 8	
1.4.4 Immunogenicity, 9	
1.4.5 Mutagenesis for Molecule Optimization, 9	
1.5 Manufacturing, 10	
1.5.1 Upstream Process, 10	
1.5.2 Downstream Process, 12	
1.5.3 Formulation, 13	
1.5.4 Process Economies, 13	
1.5.5 Glycosylation, 14	
1.6 Regulatory Challenges, 15	
1.7 Competition and Market, 16	
1.8 Conclusion and Future Perspective, 17	
References, 18	
2 Analyzing and Forecasting the Fusion Protein Market and Pipeline	25
<i>Mark Belsey and Giles Somers</i>	
2.1 Introduction, 25	
2.2 Market Sales Dynamics of the FP Market, 25	

- 2.2.1 Enbrel Founded the FP Market Following Its Launch in 1998, 26
- 2.2.2 We Forecast the FP Market Will Grow to \$10.1 Billion by 2016, 26
- 2.2.3 Growth Drivers and Restrictors that Impact the FP Market, 27
- 2.3 Individual Drug Sales Analysis, 27
 - 2.3.1 Enbrel, 27
 - 2.3.2 Orencia, 28
 - 2.3.3 Nplate, 29
 - 2.3.4 Dulaglutide and Albiglutide, 29
 - 2.3.5 VEGFtrap-Eye, 31
- 2.4 Pipeline Database Analysis, 32
 - 2.4.1 Breakdown by Stage of Development: Half of the FP Pipeline is in Phase II, 33
 - 2.4.2 Therapeutic Focus of FPs: Oncology and Autoimmune Dominate, 33
 - 2.4.3 FPs Developers and Partners: Many Big Pharma/Big Biotech Companies Have at Least One FP in Phase II Development or Above, 34
 - 2.4.4 FP Development: Less Attractive for Earlier-Stage Drug Developers, but More Attractive for Big Pharma Licensees, 34
 - 2.4.5 FPs Deal Analysis: We Believe FPs are an Attractive Target for Multinational Drug Companies, 35
- Disclaimer, 36
- Acknowledgment, 36
- References, 36

3 Structural Aspects of Fusion Proteins Determining the Level of Commercial Success **39**

Giles Somers

- 3.1 Classification of FPs, 39
 - 3.1.1 Pharmacokinetic, Targeting, and Activity FP Components, 39
 - 3.1.2 FPs Classified by the Function of Each Component, 40
 - 3.1.3 Half-Life Extension Represents a Dominant Theme (1c–7c), 41
 - 3.1.3.1 Fc Fusion is the Half-Life Extension Standard, 41
 - 3.1.3.2 Albumin Fusion is the Most Advanced non-FcFP Half-Life Approach, 41
 - 3.1.3.3 Nonfusion Alternatives, 42
 - 3.1.4 Decoy Receptors are the Largest FP Group and Well Validated (1c), 43
 - 3.1.5 Extended Half-Life Ligands (4c), 43
 - 3.1.6 FPs Offer a Wide Range of Cell Death Mechanisms (3a–7b), 44
 - 3.1.6.1 Targeted Toxins (3a and 3b), 44
 - 3.1.6.2 Targeted Ligands (4a and 4b), 45
 - 3.1.6.3 Antigen-Mediated Cell Death (5a and 5b), 46
 - 3.1.7 Antibody Fragment Fusions (6b and 7b), 46
 - 3.1.7.1 Bispecific Abs: Ab-Binding Domain Fused to Ab-Binding Domain (6b), 46
 - 3.1.7.2 Miniaturized Abs: Ab-Binding Domain Fused to Fc Effector (7b), 47
 - 3.1.7.3 Other Ab Fragment Structures, 47
 - 3.1.8 Ab- and non-Ab-Targeting Decisions, 47
 - 3.1.9 Targeted Enzymes (2a), 48
- 3.2 Factors for Commercial Success, 49
 - 3.2.1 Administration, 49
 - 3.2.2 Efficacy Profile, 50

- 3.2.3 Safety Profile, 51
- 3.2.4 Cost Factors, 52
 - 3.2.4.1 Manufacturing and Cost of Goods Sold, 52
 - 3.2.4.2 Intellectual Property: Freedom to Operate and Protection from Copies, 53

References, 54

4 Fusion Protein Linkers: Effects on Production, Bioactivity, and Pharmacokinetics 57

Xiaoying Chen, Jennica Zaro, and Wei-Chiang Shen

- 4.1 Introduction, 57
- 4.2 Overview of General Properties of Linkers Derived From Naturally Occurring Multidomain Proteins, 58
 - 4.2.1 Length of Linker Sequence, 58
 - 4.2.2 Preference of Amino Acid Residues in Linker Sequence, 58
 - 4.2.3 Hydrophobicity of Linkers, 59
 - 4.2.4 Secondary Structures of Linkers, 59
- 4.3 Empirical Linkers in Recombinant Fusion Proteins, 59
 - 4.3.1 Flexible Linkers, 59
 - 4.3.1.1 Flexible Glycine and Serine Linkers, 59
 - 4.3.1.2 Other Flexible Linkers, 60
 - 4.3.2 Rigid Linkers, 61
 - 4.3.2.1 Alpha Helix-Forming Linker (EAAAK)_n, 61
 - 4.3.2.2 Rigid (XP)_n Linkers, 62
 - 4.3.3 *In Vivo* Cleavable Linkers, 62
 - 4.3.3.1 *In Vivo* Cleavable Disulfide Linker, 62
 - 4.3.3.2 *In Vivo* Cleavable Protease-Sensitive Linkers, 64
- 4.4 Functionality of Linkers in Fusion Proteins, 66
 - 4.4.1 Linkers Can Improve Biological Activity of Fusion Proteins, 66
 - 4.4.2 Linkers Can Increase Expression Yield of Fusion Proteins, 67
 - 4.4.3 Linkers Can Affect the PK of Fusion Proteins, 68
- 4.5 Conclusions and Future Perspective, 70
- References, 71

5 Immunogenicity of Therapeutic Fusion Proteins: Contributory Factors and Clinical Experience 75

Vibha Jawa, Leslie Cousens, and Anne S. De Groot

- 5.1 Introduction, 75
- 5.2 Basis of Therapeutic Protein Immunogenicity, 75
 - 5.2.1 Relevance to Fusion Proteins, 77
- 5.3 Tools for Immunogenicity Screening, 77
 - 5.3.1 *In Silico* Analysis Tools, 77
 - 5.3.2 *In Vitro* Analysis Tools, 79
- 5.4 Approaches for Risk Assessment and Minimization, 81
 - 5.4.1 Importance to Product Development, 81
 - 5.4.2 De-immunization by Epitope Modification, 82
 - 5.4.3 Tolerance Induction, 82
 - 5.4.4 Regulatory T-Cell Epitopes in IgG Framework Regions: Tregitopes, 83
- 5.5 Case Study and Clinical Experience, 83
 - 5.5.1 Observed Versus Predicted Immunogenicity of 21 Antibodies in Clinical Use, 83

5.5.2	Correlation of Clinical Immunogenicity of Fusion Proteins with <i>In Silico</i> Risk Estimates, 83	
5.6	Preclinical and Clinical Immunogenicity Assessment Strategy, 85	
5.6.1	Strategy and Recommendation, 85	
5.7	Conclusions, 87	
	Acknowledgment, 87	
	References, 87	
PART II	THE TRIPLE T PARADIGM: TIME, TOXIN, TARGETING	91
IIA	TIME: FUSION PROTEIN STRATEGIES FOR HALF-LIFE EXTENSION	93
6	Fusion Proteins for Half-Life Extension	93
	<i>Stefan R. Schmidt</i>	
6.1	Introduction, 93	
6.2	Half-Life Extension Through Size and Recycling, 94	
6.2.1	Direct Genetic Fusions, 94	
6.2.1.1	Albumin Fusions, 94	
6.2.1.2	Fc Fusions, 97	
6.2.1.3	Transferrin Fusions, 99	
6.2.2	Half-Life Extension Through Attachment to Large Proteins, 99	
6.3	Half-Life Extension Through Increase of Hydrodynamic Radius, 100	
6.3.1	Repetitive Peptide Fusions, 100	
6.3.2	Glycosylated Peptides, 101	
6.4	Aggregate Forming Peptide Fusions, 102	
6.5	Other Concepts, 103	
6.6	Conclusions and Future Perspective, 103	
	References, 104	
7	Monomeric Fc-Fusion Proteins	107
	<i>Baisong Mei, Susan C. Low, Snejana Krassova, Robert T. Peters, Glenn F. Pierce, and Jennifer A. Dumont</i>	
7.1	Introduction, 107	
7.2	FcRn and Monomeric Fc-Fusion Proteins, 108	
7.2.1	FcRn Expression and Function, 108	
7.2.2	FcRn for the Delivery of Fc-Fusion Proteins, 108	
7.3	Typical Applications, 109	
7.3.1	Interferon Beta-Fc Monomer, 110	
7.3.2	Interferon α -Fc Monomer, 110	
7.3.3	Factor VIII-Fc Monomer, 111	
7.3.4	Factor IX-Fc Monomer, 113	
7.4	Alternative Applications, 114	
7.4.1	Follicle Stimulating Hormone-Fc-Fusion Proteins, 115	
7.4.2	Cytokine-Fc-Fusion Proteins, 115	
7.5	Expression and Purification of Monomeric Fc-Fusion Proteins, 116	
7.6	Conclusions and Future Perspectives, 118	
	References, 118	
8	Peptide-Fc Fusion Therapeutics: Applications and Challenges	123
	<i>Chichi Huang and Ronald V. Swanson</i>	
8.1	Introduction, 123	

- 8.2 Peptide Drugs, 124
 - 8.2.1 The Limitations of Native Endogenous Peptides in Drug Development, 124
 - 8.2.2 Chemical Modification of Peptides to Reduce Proteolytic Degradation, 124
 - 8.2.3 Constraining Peptides to be More Resistant to Protease Cleavage, 125
 - 8.2.4 Peptide Therapeutics Play an Important Role in Drug Development, 125
 - 8.2.5 Most Peptide Drugs Act as Receptor Agonists, 125
- 8.3 Technologies Used for Reducing *In Vivo* Clearance of Therapeutic Peptides, 126
 - 8.3.1 PEGylation, 126
 - 8.3.2 Human Serum Albumin Fusions, 126
 - 8.3.3 Other Approaches, 127
- 8.4 Fc-Fusion Proteins in Drug Development, 127
 - 8.4.1 The Structure of Fc-Fusion Proteins, 127
 - 8.4.2 Fc-Fusion Therapeutics, 127
 - 8.4.2.1 Enbrel[®], 128
 - 8.4.2.2 Amevive[®], 128
 - 8.4.2.3 Orencia[®], 129
 - 8.4.2.4 Arcalyst[®] (Also Known as IL-1 Trap or Rilonacept), 129
 - 8.4.2.5 Other Fc-Fusion Protein Therapeutics, 131
- 8.5 Peptide-Fc-Fusion Therapeutics, 131
 - 8.5.1 Peptibody, 131
 - 8.5.1.1 NPlate[®] (Romiplostim, AMG531), 131
 - 8.5.1.2 AMG 386 (2xCon4(C)), 131
 - 8.5.1.3 A-623 (AMG 623), 132
 - 8.5.1.4 Dulaglutide (LY2189265), 132
 - 8.5.2 Mimetibody[™] Technology, 133
 - 8.5.2.1 CNTO 528/CNTO 530, 133
 - 8.5.2.2 CNTO736, 133
- 8.6 Considerations and Challenges for Engineering Peptide-Fc-Fusion Therapeutics, 133
 - 8.6.1 Improving Activity, 134
 - 8.6.2 Improving Stability, 134
 - 8.6.3 Improving Pharmacokinetic Profile, 135
 - 8.6.4 Improving Solubility and Reducing Aggregation, 135
 - 8.6.5 Reducing Heterogeneity, 135
 - 8.6.6 Isotype Selection, 137
 - 8.6.7 Tailoring Fc-Effector Functions to Fit Individual Needs, 137
 - 8.6.8 Reducing Immunogenicity, 138
- 8.7 Conclusions, 138
- Acknowledgment, 138
- References, 138

9 Receptor-Fc and Ligand Traps as High-Affinity Biological Blockers: Development and Clinical Applications 143

Aris N. Economides and Neil Stahl

- 9.1 Introduction, 143
- 9.2 Etanercept as a Prototypical Receptor-Fc-Based Cytokine Blocker, 144
- 9.3 Heteromeric Traps for Ligands Utilizing Multicomponent Receptor Systems with Shared Subunits, 144

- 9.3.1 Proof-of-Concept for High-Affinity Traps for Ligands Utilizing Multicomponent Receptor Systems, 148
- 9.3.2 Turning Heterodimeric Soluble Receptor-Based Ligand Traps into Therapeutics, 150
- 9.4 Development and Clinical Application of an Interleukin 1 Trap: Rilonacept, 151
- 9.5 Development and Clinical Application of a VEGF Trap, 151
- 9.6 “To Trap Or Not To Trap?” Advantages and Disadvantages of Receptor-Fc Fusions and Traps Versus Antibodies, 152
 - 9.6.1 Multiple Ligand Binding, 152
 - 9.6.2 Signaling of Receptor-Fc Fusions, 154
 - 9.6.3 Immunogenicity, 155
- 9.7 Conclusion, 155
- Acknowledgment, 155
- References, 155

10 Recombinant Albumin Fusion Proteins 163

Thomas Weimer, Hubert J. Metzner, and Stefan Schulte

- 10.1 Concept, 163
- 10.2 Technological Aspects, 164
- 10.3 Typical Applications and Indications, 164
 - 10.3.1 Albumin Fusion Proteins in Late-Stage Development, 167
 - 10.3.1.1 Interferon- α , 167
 - 10.3.1.2 Glucagon-Like Peptide-1, 167
 - 10.3.1.3 Granulocyte Colony-Stimulating Factor, 168
 - 10.3.2 Albumin Fusion Proteins in Early-Stage Development, 168
 - 10.3.2.1 Interleukin-2, 168
 - 10.3.2.2 Insulin, 168
 - 10.3.2.3 Growth Hormone, 169
 - 10.3.2.4 Butyrylcholinesterase and Cocaine Hydrolase, 169
 - 10.3.2.5 B-Type Natriuretic Peptide, 169
 - 10.3.2.6 Erythropoietin, 170
 - 10.3.2.7 Barbourin, 170
 - 10.3.2.8 Hirudin, 170
 - 10.3.2.9 Factor VII, 170
 - 10.3.2.10 Factor IX, 171
 - 10.3.2.11 Infestin-4, 171
 - 10.3.2.12 Thioredoxin, 172
 - 10.3.2.13 Thymosin- α 1, 172
 - 10.3.2.14 Antibody Fragments, 172
- 10.4 Successes and Failures in Preclinical and Clinical Research, 172
 - 10.4.1 Interferon- α , 172
 - 10.4.2 FVII and FIX, 173
- 10.5 Challenges, 173
- 10.6 Future Perspectives, 174
- 10.7 Conclusion, 174
- Acknowledgment, 174
- References, 174

11 Albumin-Binding Fusion Proteins in the Development of Novel Long-Acting Therapeutics 179

Adam Walker, Gráinne Dunlevy, and Peter Topley

- 11.1 Introduction, 179
- 11.2 Clinically Validated Half-Life Extension Technologies—An Overview, 180

- 11.2.1 PEGylation, 180
- 11.2.2 Serum Albumin Fusion, 180
- 11.2.3 Anti-Serum Albumin Domain Antibodies in the Development of Novel Half-Life Extension Technologies, 181
- 11.3 Interferon- α Fused to Human Serum Albumin or AlbuDAb—A Direct Comparison of HSA and AlbuDAb Fusion Technologies, 182
 - 11.3.1 *In Vitro* Potency of HSA and AlbuDAb Fusion Proteins, 182
 - 11.3.2 Pharmacokinetics of HSA and AlbuDAb Fusion Proteins, 184
 - 11.3.3 *In Vivo* Efficacy of HSA and AlbuDAb Fusion Proteins, 185
- 11.4 Nanobodies in the Development of Alternative Half-Life Extension Technologies Based on Single Immunoglobulin Variable Domains, 186
- 11.5 Novel Half-Life Extension Technologies—Alternative Approaches to Single Immunoglobulin Variable Domains, 187
 - 11.5.1 Serum Albumin Binding Peptides, 187
 - 11.5.2 Serum Albumin Binding Small Molecules, 187
 - 11.5.3 Hydrophilic Polymers, 187
- 11.6 Conclusions, 188
- References, 189

12 Transferrin Fusion Protein Therapies: Acetylcholine Receptor-Transferrin Fusion Protein as a Model 191

Dennis Keefe, Michael Heartlein, and Serene Josiah

- 12.1 Disease Overview, 191
- 12.2 Fusion Protein SHG2210 Design, 192
- 12.3 Characterization of SHG2210, 193
 - 12.3.1 SHG2210 Binding and Internalization Studies in Cells, 193
 - 12.3.2 SHG2210 Anti-AchR Antibody Binding Studies, 193
 - 12.3.3 SHG2210: Anti-AchR Antibody Complex Binding and Internalization Studies in Cells, 194
 - 12.3.4 SHG2210 and SHG2210: Anti-AChR Antibody Complex Recycling Studies in Cells, 195
 - 12.3.5 Antigenic Modulation Studies, 195
 - 12.3.6 Summary of *In Vitro* Studies of SHG2210, 196
- 12.4 Applications and Indications, 196
- 12.5 Future Perspectives, 197
- 12.6 Conclusion, 198
- References, 198

13 Half-Life Extension Through O-Glycosylation 201

Fuad Fares

- 13.1 Introduction, 201
- 13.2 The Role of O-Linked Oligosaccharide Chains in Glycoprotein Function, 202
- 13.3 Designing Long-Acting Agonists of Glycoprotein Hormones, 203
 - 13.3.1 Construction of Chimeric Genes and Expression Vectors, 204
 - 13.3.2 Expression of Chimeric Genes, 204
 - 13.3.3 Bioactivity of Designed Long-Acting Glycoproteins, 205
 - 13.3.3.1 Follicle-Stimulating Hormone, 205
 - 13.3.3.2 Thyrotropin(TSH), 205

13.3.3.3	Erythropoietin (EPO), 205	
13.3.3.4	Human Growth Hormone (GH), 206	
13.4	Conclusions, 207	
	References, 207	
14	ELP-Fusion Technology for Biopharmaceuticals	211
	<i>Doreen M. Floss, Udo Conrad, Stefan Rose-John, and Jürgen Scheller</i>	
14.1	Introduction, 211	
14.2	ELP-based Protein Purification, 212	
14.3	ELPylated Proteins in Medicine and Nanobiotechnology, 215	
14.4	Molecular Pharming: a New Application for ELPylation, 217	
14.5	Challenges and Future Perspectives, 221	
14.6	Conclusion, 222	
	References, 222	
15	Ligand-Receptor Fusion Dimers	227
	<i>Sarbendra L. Pradhananga, Ian R. Wilkinson, Eric Ferrandis, Peter J. Artymiuk, Jon R. Sayers, and Richard J. Ross</i>	
15.1	Introduction, 227	
15.2	The GHLR-Fusions, 228	
15.3	Expression and Purification, 229	
15.4	Analysis of the LR-Fusions, 229	
15.4.1	Characterization, 229	
15.4.2	Biological Activity, 230	
15.4.3	Pharmacokinetics, 230	
15.4.4	Pharmacodynamics, 232	
15.4.5	Immunogenicity, 233	
15.4.6	Toxicology, 234	
15.5	LR-Fusions: The Next Generation in Hormone Treatment, 234	
15.6	Conclusion, 234	
	References, 234	
16	Development of Latent Cytokine Fusion Proteins	237
	<i>Lisa Mullen, Gill Adams, Rewas Fatah, David Gould, Anne Rigby, Michelle Sclanders, Apostolos Koutsokeras, Gayatri Mittal, Sandrine Vessillier, and Yuti Chernajovsky</i>	
16.1	Introduction, 237	
16.2	Description of Concept, 238	
16.3	Limitations of the Latent Cytokine Technology, 240	
16.4	Generation of Latent Cytokines, 242	
16.4.1	Molecular Design, 242	
16.4.2	Expression of LAP-Fusion Proteins, 243	
16.4.3	Purification of LAP-Fusion Proteins, 243	
16.5	Applications and Potential Clinical Indications, 244	
16.5.1	Multiple Sclerosis, 244	
16.5.1.1	Interferon β , 244	
16.5.1.2	Interleukin 10, 245	
16.5.1.3	Erythropoietin, 245	
16.5.1.4	Transforming Growth Factor- β , 245	
16.5.2	Rheumatoid Arthritis, 245	
16.5.2.1	Interferon β , 245	
16.5.2.2	Interleukine 10, 246	
16.5.2.3	Interleukine 4, 246	

- 16.6 Alternatives/Variants of Approach, 246
- 16.7 Challenges (Production and Development), 247
- 16.8 Conclusions and Future Perspectives, 248
- Acknowledgments, 249
- References, 249

IIB TOXIN: CYTOTOXIC FUSION PROTEINS 253

17 Fusion Proteins with Toxic Activity 253

Stefan R. Schmidt

- 17.1 Introduction, 253
- 17.2 Toxins, 254
 - 17.2.1 Microbial Toxins, 254
 - 17.2.2 Plant Toxins, 257
- 17.3 Immunocytokines, 258
 - 17.3.1 Interleukin 2 Fusion Proteins, 258
 - 17.3.2 GM-CSF Fusion Proteins, 258
 - 17.3.3 Other Leukocyte Attracting Cytokines and Chemokines, 258
- 17.4 Human Enzymes, 259
 - 17.4.1 Kinases, 259
 - 17.4.2 RNAses, 259
 - 17.4.3 Proteases, 260
 - 17.4.4 Antibody-Directed Enzyme Prodrug Therapy, 260
- 17.5 Apoptosis Induction, 261
 - 17.5.1 TNF Fusion Proteins, 261
 - 17.5.2 FasL Fusion Proteins, 262
 - 17.5.3 TRAIL Fusion Proteins, 262
 - 17.5.4 Intrinsic Apoptosis Inducing Fusion Proteins, 263
- 17.6 Fc-Based Toxicity, 263
 - 17.6.1 Antibody-Derived Cellular Cytotoxicity (ADCC), 263
 - 17.6.2 Antibody-Dependent Cell-Mediated Phagocytosis (ADCP), 264
 - 17.6.3 Complement-Dependent Cytotoxicity (CDC), 264
 - 17.6.4 Complement-Dependent Cell-Mediated Cytotoxicity (CDCC), 264
- 17.7 Peptide-Based Toxicity, 264
- 17.8 Conclusions and Future Perspectives, 265
- References, 265

18 Classic Immunotoxins with Plant or Microbial Toxins 271

Jung Hee Woo and Arthur Frankel

- 18.1 Introduction, 271
- 18.2 Toxins Used in Immunotoxin Preparation, 272
 - 18.2.1 Diphtheria Toxin, 272
 - 18.2.2 Pseudomonas Exotoxin, 272
 - 18.2.3 Ricin, 274
 - 18.2.4 Gelonin and Saporin, 274
- 18.3 Immunotoxin Design and Synthesis, 274
- 18.4 Clinical Update of Immunotoxin Trials, 278
- 18.5 Challenges and Perspective of Classic Immunotoxins, 284
 - 18.5.1 Adverse Events, 284
 - 18.5.2 Immunogenicity, 285
- 18.6 Conclusions, 286
- References, 286

19 Targeted and Untargeted Fusion Proteins: Current Approaches to Cancer Immunotherapy	295
<i>Leslie A. Khawli, Peisheng Hu, and Alan L. Epstein</i>	
19.1 Introduction, 295	
19.2 Immunotherapeutic Strategy for Cancer: Fusion Proteins, 296	
19.3 Immunotherapeutic Applications of Antibody-Targeted and Untargeted Fc Fusion Proteins, 297	
19.3.1 Cytokine Fusion Proteins, 298	
19.3.2 Chemokine Fusion Proteins, 299	
19.3.3 Co-Stimulatory Fusion Proteins, 299	
19.3.3.1 B7.1 Fusion Proteins, 300	
19.3.3.2 CD137L Fusion Proteins, 301	
19.3.3.3 GITRL Fusion Proteins, 301	
19.3.3.4 OX40L Fusion Proteins, 302	
19.3.4 Enzyme Fusion Proteins, 303	
19.3.5 Vascular Targeting Fusion Proteins, 304	
19.4 Combination Fusion Proteins Therapy, 305	
19.4.1 Cytokine Fusion Protein Combinations, 305	
19.4.2 Chemokine and Cytokine Synergy, 306	
19.4.3 Co-Stimulatory Fusion Protein Combinations, 306	
19.5 Mechanism of Action: Immunoregulatory T-Cell (T _{reg}) Depletion and Fusion Protein Combination Therapy, 306	
19.5.1 LEC Fusion Proteins in Combination with T _{reg} Depletion, 307	
19.5.2 CD137L and GITRL Fusion Proteins in Combination with T _{reg} Depletion, 308	
19.6 Future Directions, 309	
19.7 Conclusion, 309	
Acknowledgments, 310	
References, 310	
20 Development of Experimental Targeted Toxin Therapies for Malignant Glioma	315
<i>Nikolai G. Rainov and Volkmar Heidecke</i>	
20.1 Introduction, 315	
20.2 Targeted Toxins—General Considerations, 316	
20.3 Delivery Mode and Pharmacokinetics of Targeted Toxins in the Brain, 316	
20.4 Preclinical and Clinical Studies with Targeted Toxins, 318	
20.4.1 IL4-PE (NBI-3001), 318	
20.4.2 TP-38, 319	
20.4.3 IL13-PE38, 320	
20.4.4 TransMID-107 (Tf-CRM107), 322	
20.5 Conclusions and Future Developments of Targeted Toxins, 324	
Disclosure, 325	
References, 325	
21 Immunokinases	329
<i>Stefan Barth, Stefan Gattenlöhner, and Mehmet Kemal Tur</i>	
21.1 Introduction, 329	
21.2 Protein Kinases, Apoptosis, and Cancer, 330	
21.2.1 General Properties of Protein Kinases, 330	
21.2.2 Death-Associated Protein Kinases (DAPKs), 330	

21.2.3	The Role of DAPK1 and DAPK2 in Cancer, 331	
21.3	Therapeutic Strategies to Restore Missing Kinase Expression, 331	
21.3.1	Systemic Delivery of Demethylating Agents, 331	
21.3.2	Nontargeted Reactivation of Specific Protein Kinases, 332	
21.3.3	Targeted Reactivation of Specific Protein Kinases Using DAPK2-Based Immunokinases, 332	
21.4	Analysis of Immunokinase Efficacy, 333	
21.4.1	<i>In Vitro</i> Activity of Recombinant Immunokinase DAPK2'-CD30L, 333	
21.4.2	<i>In Vivo</i> Activity of Recombinant Immunokinase DAPK2'-CD30L, 333	
21.5	Outlook, 334	
	References, 334	
22	ImmunoRNase Fusions	337
	<i>Wojciech Ardelt</i>	
22.1	Introduction, 337	
22.1.1	Immunotoxins, 337	
22.1.2	Cytotoxic Activity of Ribonucleases, 337	
22.1.3	Ribonuclease Targeting to Cancer Cells, 338	
22.2	Development of ImmunoRNase Fusion Proteins as Biopharmaceuticals, 339	
22.2.1	Immuno-Fusion Proteins of Eosinophil-Derived Endotoxin or Angiogenin, 339	
22.2.2	Immuno-Fusion Proteins of Bovine Seminal Plasma RNase or Human Pancreatic RNase, 341	
22.2.3	Immuno-Fusion Proteins of Onconase [®] or <i>Rana Pipiens</i> Liver RNase, 342	
22.2.4	Barnase Immuno-Fusion Proteins, 343	
22.3	Aspects of ImmunoRNase Design and Production, 344	
22.3.1	Molecular Size and Valency, 344	
22.3.2	Interaction with Mammalian RNase Inhibitor, 344	
22.3.3	Cleavable ImmunoRNases, 345	
22.3.4	High-Level Production of ImmunoRNases, 345	
22.4	Alternatives, 346	
22.5	Conclusions and Future Perspectives, 347	
	References, 347	
23	Antibody-Directed Enzyme Prodrug Therapy (ADEPT)	355
	<i>Surinder K. Sharma</i>	
23.1	Introduction, 355	
23.2	The Components, 355	
23.2.1	The Target, 355	
23.2.2	The Antibody, 356	
23.2.3	The Enzyme, 356	
23.2.4	Abzymes or Catalytic Antibodies, 357	
23.2.5	Prodrugs, 357	
23.3	ADEPT Systems with Carboxypeptidase G2 (CPG2), 357	
23.3.1	System 1: Antibody-Enzyme Conjugates, 357	
23.3.1.1	Preclinical Studies, 357	
23.3.1.2	Removal of Enzyme Activity from Blood, 357	
23.3.1.3	First in Man ADEPT Study, 358	
23.3.1.4	Results of the First in Man ADEPT Study, 358	
23.3.1.5	Conclusions from the First in Man ADEPT Study, 358	

23.3.2	The Second Clinical Study of ADEPT, 358	
23.3.2.1	Conclusions from the Second Clinical Study of ADEPT, 359	
23.3.3	The Third Clinical Study of ADEPT, 359	
23.3.3.1	Conclusions from the Third Clinical Study of ADEPT, 359	
23.4	Fusion Proteins, 359	
23.4.1	The Fourth Clinical Study of ADEPT, 360	
23.5	Immunogenicity, 360	
23.6	Conclusions and Future Outlook, 361	
	Acknowledgments, 361	
	References, 361	
24	Tumor-Targeted Superantigens	365
	<i>Gunnar Hedlund, Göran Forsberg, Thore Nederman, Anette Sundstedt, Leif Dahlberg, Mikael Tiensuu, and Mats Nilsson</i>	
24.1	Introduction: Tumor-Targeted Superantigens—A Unique Concept of Cancer Treatment, 365	
24.2	Structure and Production of Tumor-Targeted Superantigens, 366	
24.3	Tumor-Targeted Superantigens are Powerful Targeted Immune Activators and Useful for all Types of Malignancies, 367	
24.4	Increasing the Therapeutic Window and Exposure by the Creation of a Novel TTS Fusion Protein with Minimal MHC Class II Affinity; Naptumomab Estafenatox, 370	
24.5	Clinical Experience with TTS Therapeutic Fusion Proteins, 371	
24.5.1	Anatumomab Mafenatox, 371	
24.5.2	Naptumomab Estafenatox, 372	
24.6	Combining TTS with Cytostatic and Immunomodulating Anticancer Drugs, 377	
24.7	Conclusions, 379	
	References, 379	
IIC	TARGETING: FUSION PROTEINS ADDRESSING SPECIFIC CELLS, ORGANS, AND TISSUES	383
25	Fusion Proteins with a Targeting Function	383
	<i>Stefan R. Schmidt</i>	
25.1	Introduction, 383	
25.2	Targeting Organs, 383	
25.2.1	Brain, 383	
25.2.2	Liver, 385	
25.2.3	Lung, 386	
25.2.4	Bone, 387	
25.2.5	Thrombus Targeting, 387	
25.3	Intracellular Delivery, 388	
25.3.1	Enzyme Replacement Therapy, 388	
25.3.2	Cell Penetrating Peptides, 389	
25.3.3	Antibody-Mediated Transduction, 390	
25.3.4	Endosome Escape and Cytosol Translocation, 390	
25.4	Oral Delivery, 391	
25.5	Conclusions and Future Perspectives, 392	
	References, 393	

- 26 Cell-Penetrating Peptide Fusion Proteins 397**
Andrés Muñoz-Alarcón, Henrik Helmfors, Kristin Karlsson, and Ülo Langel
- 26.1 Introduction, 397
 - 26.2 Typical Applications and Indications, 397
 - 26.3 Technological Aspects, 399
 - 26.3.1 Creating CPP-Fusion Proteins, 399
 - 26.3.2 Recombinant Fusion Protein Expression Systems, 399
 - 26.3.3 Disulfide Bond, 400
 - 26.3.4 Biotin-Avidin Fusion Model, 401
 - 26.3.5 Expressed Protein Ligation, 401
 - 26.3.6 Purification, 401
 - 26.3.7 Purification Tag, 401
 - 26.3.8 Affinity Chromatography, 401
 - 26.3.9 Solid Phase Peptide Synthesis and High Performance Liquid Chromatography, 402
 - 26.4 Successes and Failures in Preclinical and Clinical Research, 402
 - 26.4.1 Preclinical Research, 402
 - 26.4.2 CPPs Used in Clinical Trials, 403
 - 26.5 Alternatives/Variants of This Approach, 405
 - 26.6 Conclusions and Future Perspectives, 405
 - Acknowledgments, 406
 - References, 406
- 27 Cell-Specific Targeting of Fusion Proteins through Heparin Binding 413**
Jiajing Wang, Zhenzhong Ma, and Jeffrey A. Loeb
- 27.1 Why Target Heparan-Sulfate Proteoglycans with Fusion Proteins?, 413
 - 27.2 Heparan Sulfate Structure and Biosynthesis Create Diversity and a Template for Targeting Specificity, 415
 - 27.3 Tissue-Specific Expression of HSPGs and the Enzymes That Modify Them, 416
 - 27.4 Heparin-Binding Proteins and Growth Factors, 416
 - 27.5 Viruses Target Cells Through Heparin Binding, 417
 - 27.6 Dissecting Heparin-Binding Protein Domains for Tissue-Specific Targeting, 418
 - 27.7 Fusion Proteins Incorporating HBDs, 418
 - 27.8 The Neuregulin 1 Growth Factor Has a Unique and Highly Specific HBD, 419
 - 27.9 Using Neuregulin's HBD to Generate a Targeted Neuregulin Antagonist, 419
 - 27.10 Tissue Targeting and Therapeutic Efficacy of a Heparin-Targeted NRG1 Antagonist Fusion Protein, 420
 - 27.11 Conclusions and Future Perspectives, 423
 - References, 424
- 28 Bone-Targeted Alkaline Phosphatase 429**
José Luis Millán
- 28.1 Detailed Description of the Concept, 429
 - 28.2 Technical Aspects, 430
 - 28.3 Applications and Indications, 432
 - 28.4 Preclinical and Clinical Research, 433

- 28.5 Alternatives/Variants of This Approach, 434
- 28.6 Challenges in Production and Development, 436
- 28.7 Conclusions and Future Perspectives, 436
- Acknowledgments, 437
- References, 437

29 Targeting Interferon- α to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery **441**

Jessica Fioravanti, Jesús Prieto, and Pedro Berraondo

- 29.1 Detailed Description of the Concept, 441
 - 29.1.1 Interferons, 441
 - 29.1.2 Stabilization of IFN- α , 442
 - 29.1.3 IFN- α Liver Targeting, 443
 - 29.1.4 Apolipoprotein A-I as a Scaffold for Peptide and Protein Delivery, 444
 - 29.1.5 Stabilization and Liver Targeting of IFN- α by Apolipoprotein A-I, 445
 - 29.1.6 Unexpected Properties of the Fusion Protein of Interferon- α and Apolipoprotein A-I, 446
- 29.2 Technological Aspects, 447
- 29.3 Typical Applications and Indications, 447
- 29.4 Alternatives and Variants of This Approach, 448
- 29.5 Conclusions and Future Perspectives, 448
- References, 448

PART III BEYOND THE TRIPLE T-PARADIGM **453**

IIIA NOVEL CONCEPTS, NOVEL SCAFFOLDS **455**

30 Signal Converter Proteins **455**

Mark L. Tykocinski

- 30.1 Introduction, 455
- 30.2 Historical Roots of Signal Conversion: Artificial Veto Cell Engineering and Protein Painting, 455
 - 30.2.1 Artificial Veto Cell Engineering, 456
 - 30.2.2 Protein Painting, 457
- 30.3 Trans Signal Converter Proteins, 458
- 30.4 Expanding Trans Signal Conversion Options: Redirecting Signals, 459
- 30.5 From Trans to Cis Signal Conversion: Driving Auto-Signaling, 460
- 30.6 Mechanistic Dividends of Chimerization, 461
- 30.7 Targeting Multiple Diseases with Individual Signal Converters, 462
- 30.8 Structural Constraints in SCP Design, 463
- 30.9 Coding SCP Functional Repertoires, 463
- 30.10 Expanding the Catalog of Inhibitory SCP, 464
- 30.11 Immune Activating SCP, 466
- 30.12 Experimental Tools for Screening SCP Candidates, 467
- 30.13 SCP Frontiers: Mining the Surface Protein Interactome, Rewiring Cellular Networks, 467
- References, 468

Soluble T-Cell Antigen Receptors **475***Peter R. Rhode*

- 31.1 Soluble T-cell Antigen Receptor (STAR) Fusion Technology and Utilities, 475
 - 31.1.1 Three Domains Single-Chain TCR (scTCR) Format and scTCR-Fusions, 476
 - 31.1.2 Mutagenesis and Multimerization for Improved Target Recognition, 477
- 31.2 Expression and Purification of Recombinant Star Fusion Proteins, 477
- 31.3 Clinical and Research Product Applications, 478
 - 31.3.1 Cancer Therapeutics, 478
 - 31.3.2 Viral Therapeutics, 479
 - 31.3.3 Diagnostic and Research Applications, 480
- 31.4 Preclinical Testing Using Star Fusion Proteins, 481
 - 31.4.1 Preclinical Efficacy, Pharmacokinetic, and Toxicity Studies, 481
 - 31.4.2 Antitumor Mechanism-of-Action Studies of ALT-801, 483
 - 31.4.3 Preclinical Efficacy Studies of Anticancer p53 Specific scTCRIgG1 Fusion Proteins, 485
 - 31.4.4 Evaluation of Combination p53-Specific STAR Fusion Protein and Chemotherapy Regimens in Tumor Efficacy Models, 486
- 31.5 Clinical Development of ALT-801, 487
 - 31.5.1 Monotherapy Clinical Study with ALT-801, 487
 - 31.5.2 ALT-801/Chemotherapy Phase II Studies, 487
- 31.6 Alternatives/Variants of This Approach, 488
 - 31.6.1 Development of Novel TCR-Targeted IL-15 Superagonist Fusions, 488
 - 31.6.2 Cell-Based Therapies, 489
- 31.7 Challenges, 489
- 31.8 Conclusions and Future Perspectives, 490
- Acknowledgments, 490
- References, 490

12 High-Affinity Monoclonal T-Cell Receptor (mTCR) Fusions **495***Nikolai M. Lissin, Namir J. Hassan, and Bent K. Jakobsen*

- 32.1 Introduction: The T Cell Receptor (TCR) as a Targeting Molecule, 495
- 32.2 Engineered High-Affinity Monoclonal TCRs (mTCR), 497
- 32.3 mTCR-Based Fusion Proteins for Therapeutic Applications, 500
- 32.4 Immune-Mobilizing Monoclonal TCRs Against Cancer (ImmTAC), 500
- 32.5 Conclusions and Future Perspectives, 503
- Acknowledgments, 504
- References, 504

13 Amediplase **507***Stefano Evangelista and Stefano Manzini*

- 33.1 Introduction, 507
- 33.2 Source, Physico-Chemical Properties and Formulation, 508
 - 33.2.1 Production Cell Line, 508
 - 33.2.2 Drug Substance, 508
 - 33.2.3 Drug Product, 509
- 33.3 Preclinical Studies, 510
 - 33.3.1 *In Vitro* Biological Properties, 510
 - 33.3.1.1 Plasminogen Activator Activity, 510
 - 33.3.1.2 *In Vitro* Thrombolytic Activity, 510

33.3.1.3	Fibrin Specificity, 510	
33.3.1.4	Inhibition by Plasma Protease Inhibitors, 510	
33.3.1.5	Binding to Fibrin, 510	
33.3.1.6	Clot Penetration, 510	
33.3.2	Pharmacodynamics: <i>In Vivo</i> Studies, 511	
33.3.2.1	Thrombolytic Activity in Rabbits, 511	
33.3.2.2	Thrombolytic and Haemorrhagic Effects in Rabbits, 511	
33.3.2.3	Fibrinolytic Activity of Amediplase in Rats, 511	
33.3.2.4	<i>In Vivo</i> Thrombolytic Activity of Amediplase in Dogs, 511	
33.3.3	Pharmacokinetics, 511	
33.3.3.1	Pharmacokinetics of Amediplase in Monkeys, 511	
33.3.3.2	Pharmacokinetics of Amediplase in Rats, 511	
33.3.3.3	The <i>In Vivo</i> Fate of Amediplase in Rats, 512	
33.3.4	Toxicology, 512	
33.4	Human Studies, 512	
33.4.1	1K2 Study: A Phase I Single Ascending Dose Study, 512	
33.4.2	2K2 Study: A Phase II, Multicenter, Open-Label, Dose-Finding, Pilot Study, 513	
33.4.3	3K2 Study: A Double-Blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Two Doses of Amediplase, 514	
33.5	Historical Comparison with Other Thrombolytics, 517	
33.6	Conclusions and Future Perspectives, 517	
	Acknowledgment, 517	
	References, 517	
34	Breaking New Therapeutic Grounds: Fusion Proteins of Darpins and Other Nonantibody Binding Proteins	519
	<i>Hans Kaspar Binz</i>	
34.1	Introduction, 519	
34.2	Novel Scaffolds—Alternatives to Antibodies, 519	
34.2.1	Success and Limitations of Antibodies, 519	
34.2.2	Natural Binding Proteins, 520	
34.2.3	Tailoring Nonantibody Binding Proteins, 521	
34.2.4	DARPs—Designed Ankyrin Repeat Proteins, 522	
34.3	New Therapeutic Concepts with Nonantibody Binding Proteins, 523	
34.3.1	Natural Fusion Protein Examples, 523	
34.3.2	Fusion Proteins with Nonantibody Binding Proteins, 523	
34.3.2.1	Bivalent and Bispecific Molecules, 523	
34.3.2.2	Multispecific Constructs, 524	
34.3.2.3	Critical Advantage of Multispecific Nonantibody Binding Proteins, 525	
34.3.2.4	Combining Scaffolds with Other Effector Proteins, 525	
34.4	Scaffold-Fusion Proteins Beyond Antibody Possibilities, 525	
	Acknowledgments, 526	
	References, 526	
IIIB	MULTIFUNCTIONAL ANTIBODIES	529
35	Resurgence of Bispecific Antibodies	529
	<i>Patrick A. Baeuerle and Tobias Raum</i>	
35.1	A Brief History of Bispecific Antibodies, 529	
35.2	Asymmetric IgG-Like Bispecific Antibodies, 530	

- 35.3 Symmetric IgG-Like Bispecific Antibodies, 531
- 35.4 IgG-Like Bispecific Antibodies with Fused Antibody Fragments, 533
- 35.5 Bispecific Constructs Based on the Fc γ Fragment, 534
- 35.6 Bispecific Constructs Based on Fab Fragments, 535
- 35.7 Bispecific Constructs Based on Diabodies or Single-Chain Antibodies, 536
- 35.8 Bifunctional Fusions of Antibodies or Fragments with Other Proteins, 538
- 35.9 Bispecific Antibodies for Various Functions: How to Select the Right Format?, 539
- References, 541
- 36 Novel Applications of Bispecific DART[®] Proteins 545**
- Syd Johnson, Bhaswati Burat, Hua W. Li, Ralph F. Alderson, Paul A. Moore, and Ezio Bonvini*
- 36.1 Introduction, 545
- 36.2 DART[®] Proteins, 546
- 36.3 Application of DART[®] to Cross-Link Inhibitory and Activating Receptors, 546
- 36.4 Application of Bispecific Antibodies in Oncology, 547
- 36.4.1 CD16-Based DART[®] Proteins, 547
- 36.4.2 CD3/TCR-Based DART[®] Proteins, 547
- 36.5 U-DART Concept for Screening DART[®] Candidate Targets and mAbs, 549
- 36.6 U-DART Concept for Applications in Autoimmune and Inflammatory Disease, 549
- 36.6.1 Inhibition of Basophil Degranulation, 553
- 36.7 Conclusions and Future Perspectives, 554
- References, 554
- 37 Strand Exchange Engineered Domain (Seed): A Novel Platform Designed to Generate Mono and Multispecific Protein Therapeutics 557**
- Alec W. Gross, Jessica P. Dawson, Marco Muda, Christie Kelton, Sean D. McKenna, and Björn Hock*
- 37.1 Introduction, 557
- 37.2 Technical Aspects, 558
- 37.2.1 Workflow, 558
- 37.2.2 Therapeutic Formats, 560
- 37.2.3 Biophysical Properties, 561
- 37.2.4 Biological Properties, 562
- 37.3 Potential Therapeutic Applications, 562
- 37.4 Future Perspectives, 566
- 37.5 Conclusions, 567
- Acknowledgments, 567
- References, 567
- 38 CovX-Bodies 571**
- Abhijit Bhat, Olivier Laurent, and Rodney Lappe*
- 38.1 The CovX-Body Concept, 571
- 38.2 Technological Aspects, 571
- 38.2.1 Scaffold Antibody, 571
- 38.2.2 Linker Design, 575
- 38.2.3 Choice of Payload, 577
- 38.2.4 Manufacture, Process, Characterization, 578

38.3 Applications of the CovX-Body Technology, 578	
38.3.1 CVX-060, a Selective Angiopoietin-2 Targeting CovX-Body, 578	
38.3.2 CVX-241, an Example of a Bispecific Antibody, 580	
38.3.3 CVX-343, Fusion of a Small Protein with CVX-2000, 581	
References, 581	
39 Modular Antibody Engineering: Antigen Binding Immunoglobulin Fc CH3 Domains as Building Blocks for Bispecific Antibodies (mAb²)	583
<i>Maximilian Woisetschläger, Florian Rüker, Geert C. Mudde, Gordana Wozniak-Knopp, Anton Bauer, and Gottfried Himmler</i>	
39.1 Introduction, 583	
39.2 Immunoglobulin Fc as a Scaffold, 583	
39.3 Design of Libraries Based on the Human IgG1 CH3 Domain, 584	
39.4 TNF- α -Binding Fcab: Selection and Characterization of Fcab TNF353-2, 585	
39.5 Conclusions and Future Perspectives, 588	
Acknowledgments, 588	
References, 589	
40 Designer Fusion Modules for Building Multifunctional, Multivalent Antibodies, and Immunoconjugates: The Dock-and-Lock Method	591
<i>Edmund A. Rossi, David M. Goldenberg, and Chien-Hsing Chang</i>	
40.1 Introduction, 591	
40.2 DDD/AD Modules Based on PKA and AKAP, 592	
40.3 Advantages and Disadvantages of the DNL Method, 592	
40.3.1 Advantages of the DNL Method, 592	
40.3.2 Disadvantages of the DNL Method, 593	
40.4 Fab-Based Modules, 593	
40.5 IgG-AD2-Modules, 594	
40.6 Hexavalent Antibodies, 595	
40.7 More Antibody-Based-Modules and Multivalent Antibodies, 596	
40.8 Nonantibody-Based DNL Modules, 597	
40.9 IFN- α 2b-DDD2 Module and Immunocytokines, 597	
40.10 Variations on the DNL Theme, 598	
40.10.1 Alternative Linker Modules, 598	
40.10.2 Alternative Covalent Stabilization, 598	
40.11 Conclusions and Future Perspective, 599	
References, 599	